Shopping Cart 0
Cart Subtotal
USD 0

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4450

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023.

 

Market analysis

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon neurological immune system issue where myelin, a fundamental part of the nervous system is being attacked by the immune system of the body. There has been a spiraling ascent in the predominance of autoimmune disorders in the past which offers scope for the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different new medications have been propelled into the market after ongoing FDA endorsements which likewise supports the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different factors empowering the development of the market incorporate growing awareness about the disease and government attempts in the same issue. On the drawback, the mind-boggling expense of Intravenous immunoglobulin treatment and its side effects remains the major obstruction to the development of the market. The market is growing at a CAGR of 6.2% and is anticipated to reach USD 3907.17 Mn by the end of the forecast period 2018-2023.

 

Market segmentation

 

Based on its treatment & diagnosis, the global chronic inflammatory demyelinating polyneuropathy disease market is segmented as Corticosteroids, Treatment Intravenous Immunoglobulin, Electrodiagnostic Testing, Physiotherapy, Spinal Fluid Analysis, Nerve Conduction, Plasmapheresis (plasma exchange), Diagnosis, EMG, Others. By end-user, the market is segmented as Specialty Neurological Clinics, Hospitals, Research & Academic Laboratories, Others. By route of administration, the market is again bifurcated into oral, intravenous and others.

 

Regional analysis

 

Geographically, the global chronic inflammatory demyelinating polyneuropathy disease market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

 

Major players

 

Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter, among others are some of the major players in the global chronic inflammatory demyelinating polyneuropathy disease market.

READ MORE

Table Of Content

Scope

Table of Contents:

 

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition

3.2 Scope of the Study

3.3 Research Objective

3.4 Assumptions & Limitations

3.4.1 Assumptions

3.4.2 Limitations

3.5 Market Structure

4 Research Methodology

4.1 Research Process

4.2 Primary Research

4.3 Secondary Research

4.4 Market Size Estimation

4.5 Forecast Model

5 Market Dynamics

5.1 Introduction

5.2 Drivers

5.2.1 Rising prevalence of autoimmune diseases

5.2.2 Increasing research and development related to plasma-derived medicines

5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

5.3 Restraints

5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment

5.3.2 High cost of the IVIG treatment

5.4 Opportunity

5.4.1 Advancements in the treatment

5.5 Clinical Trials Data

6 Market Factor Analysis

6.1 Porter's Five Forces Model

6.1.1 Bargaining Power of Suppliers

6.1.2 Bargaining Power of Buyers

6.1.3 Threat of New Entrants

6.1.4 Threat of Substitutes

6.1.5 Intense Rivalry

6.2 Supply Chain Analysis

6.2.1 R&D and Designing

6.2.2 Manufacturing

6.2.3 Distribution & Sales

6.2.4 Post-Sales Monitoring

7 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

7.1 Introduction

7.2 Treatment

7.3 Diagnosis

8 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

8.1 Introduction

8.2 Intravenous

8.3 Oral

9 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

9.1 Introduction

9.2 Hospitals

9.3 Specialty Neurological Clinics

9.4 Research & Academic Laboratories

10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 China

10.4.2 Japan

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East and Africa

10.5.1 Middle East

10.5.2 Africa

11 Competitive Landscape

11.1 Company Market Share Analysis

11.2 Introduction

12 Company Profiles

12.1 Grifols

12.1.1 Company Overview

12.1.2 Financial Overview

12.1.3 Products/Services Offered

12.1.4 SWOT Analysis

12.1.5 Key Developments

12.1.6 Key strategy

12.2 Shire

12.2.1 Company Overview

12.2.2 Financial Overview

12.2.3 Products/Services Offered

12.2.4 SWOT Analysis

12.2.5 Key Developments

12.2.6 Key strategy

12.3 Baxter

12.3.1 Company Overview

12.3.2 Company Overview

12.3.3 Products/Services Offered

12.3.4 SWOT Analysis

12.3.5 Key Developments

12.3.6 Key strategy

12.4 Pfizer, Inc.

12.4.1 Company Overview

12.4.2 Financial Overview

12.4.3 Products/Services Offered

12.4.4 SWOT Analysis

12.4.5 Key Developments

12.4.6 Key Strategy

12.5 CSL Behring

12.5.1 Company Overview

12.5.2 Financial Overview

12.5.3 Products/Services Offered

12.5.4 SWOT Analysis

12.5.5 Key Developments

12.5.6 Key Strategy

12.6 Kedrion S.p.A

12.6.1 Company Overview

12.6.2 Financial Overview

12.6.3 Products/Services Offered

12.6.4 SWOT Analysis

12.6.5 Key Development

12.6.6 Key Strategy

12.7 Octapharma

12.7.1 Company Overview

12.7.2 Financial Overview

12.7.3 Products/Services Offered

12.7.4 SWOT Analysis

12.7.5 Key Development

12.7.6 Key Strategy

12.8 Momenta Pharmaceuticals

12.8.1 Company Overview

12.8.2 Financial Overview

12.8.3 Products/Services Offered

12.8.4 SWOT Analysis

12.8.5 Key Development

12.8.6 Key Strategy

12.9 Teijin Pharma Limited

12.9.1 Company Overview

12.9.2 Financial Overview

12.9.3 Products/Services Offered

12.9.4 SWOT Analysis

12.9.5 Key Developments

12.9.6 Key strategy

12.1 Mitsubishi Tanabe Pharma Corporation

12.10.1 Company Overview

12.10.2 Financial Overview

12.10.3 Products/Services Offered

12.10.4 SWOT Analysis

12.10.5 Key Developments

12.11 Bio Products Laboratory Ltd.

12.11.1 Company Overview

12.11.2 Financial Overview

12.11.3 Products/Services Offered

12.11.4 SWOT Analysis

12.11.5 Key Developments

12.11.6 Key strategy

13 Appendix

13.1 Discussion Blue Print


List Of Figure

List of Figures:

 

FIGURE 1 RESEARCH PROCESS

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

(CIDP) MARKET

FIGURE 4 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET

FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET

FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS,

2017 (%)

FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2017 & 2023 (USD MILLION)

FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF

ADMINISTRATION, 2017 (%)

FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2017 & 2023 (USD MILLION)

FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2017 (%)

FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2017 & 2023 (USD MILLION)

FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2017 & 2023 (USD MILLION)

FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%)

FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%)

FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE,

BY COUNTRY, 2017 (%)

FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2017 (%)


List Of Table

List of Tables:

 

TABLE 1 MARKET SYNOPSIS

TABLE 2 PRIMARY INTERVIEWS

TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION,

2015-2023 (USD MILLION)

TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION,

2015-2023 (USD MILLION)

TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRAVENOUS BY REGION,

2015-2023 (USD MILLION)

TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION,

2015-2023 (USD MILLION)

TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2015-2023 (USD MILLION)

TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION,

2015-2023 (USD MILLION)

TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS,

BY REGION, 2015-2023 (USD MILLION)

TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC

LABORATORIES, BY REGION, 2015-2023 (USD MILLION)

TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 26 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 27 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 28 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 29 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 30 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 31 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 32 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 33 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 34 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 35 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 36 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 37 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 38 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 39 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 40 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 41 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 42 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 43 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 44 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 45 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 46 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 47 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 48 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 49 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 50 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 51 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 52 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 53 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

\2015-2023 (USD MILLION)

TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 75 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 76 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 77 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 78 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 79 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 80 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 82 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 83 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 84 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 85 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 86 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 87 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 88 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 89 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 90 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 91 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 92 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 93 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 94 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

TREATMENT BY TYPE, 2015-2023 (USD MILLION)

TABLE 95 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION)

TABLE 96 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 97 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 98 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 99 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 100 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 101 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 102 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 103 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 104 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 105 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 106 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 107 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 108 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 109 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 110 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 111 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 112 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 113 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 114 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 115 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 116 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 117 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 118 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 119 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 120 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 121 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 122 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 123 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 124 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 125 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 126 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 127 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 128 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 129 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 130 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 131 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 132 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 133 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 134 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 135 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 136 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 137 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 138 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 139 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 140 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 141 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 142 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 143 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 144 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 145 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 146 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 147 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 148 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION,

2015-2023 (USD MILLION)

TABLE 149 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 150 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 151 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 152 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 153 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 154 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 155 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 156 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 157 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 158 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 159 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 160 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 161 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 162 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 163 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 164 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

Licence Rights

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023.

 

Market analysis

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon neurological immune system issue where myelin, a fundamental part of the nervous system is being attacked by the immune system of the body. There has been a spiraling ascent in the predominance of autoimmune disorders in the past which offers scope for the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different new medications have been propelled into the market after ongoing FDA endorsements which likewise supports the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different factors empowering the development of the market incorporate growing awareness about the disease and government attempts in the same issue. On the drawback, the mind-boggling expense of Intravenous immunoglobulin treatment and its side effects remains the major obstruction to the development of the market. The market is growing at a CAGR of 6.2% and is anticipated to reach USD 3907.17 Mn by the end of the forecast period 2018-2023.

 

Market segmentation

 

Based on its treatment & diagnosis, the global chronic inflammatory demyelinating polyneuropathy disease market is segmented as Corticosteroids, Treatment Intravenous Immunoglobulin, Electrodiagnostic Testing, Physiotherapy, Spinal Fluid Analysis, Nerve Conduction, Plasmapheresis (plasma exchange), Diagnosis, EMG, Others. By end-user, the market is segmented as Specialty Neurological Clinics, Hospitals, Research & Academic Laboratories, Others. By route of administration, the market is again bifurcated into oral, intravenous and others.

 

Regional analysis

 

Geographically, the global chronic inflammatory demyelinating polyneuropathy disease market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

 

Major players

 

Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter, among others are some of the major players in the global chronic inflammatory demyelinating polyneuropathy disease market.

READ MORE

Scope

Table of Contents:

 

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition

3.2 Scope of the Study

3.3 Research Objective

3.4 Assumptions & Limitations

3.4.1 Assumptions

3.4.2 Limitations

3.5 Market Structure

4 Research Methodology

4.1 Research Process

4.2 Primary Research

4.3 Secondary Research

4.4 Market Size Estimation

4.5 Forecast Model

5 Market Dynamics

5.1 Introduction

5.2 Drivers

5.2.1 Rising prevalence of autoimmune diseases

5.2.2 Increasing research and development related to plasma-derived medicines

5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

5.3 Restraints

5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment

5.3.2 High cost of the IVIG treatment

5.4 Opportunity

5.4.1 Advancements in the treatment

5.5 Clinical Trials Data

6 Market Factor Analysis

6.1 Porter's Five Forces Model

6.1.1 Bargaining Power of Suppliers

6.1.2 Bargaining Power of Buyers

6.1.3 Threat of New Entrants

6.1.4 Threat of Substitutes

6.1.5 Intense Rivalry

6.2 Supply Chain Analysis

6.2.1 R&D and Designing

6.2.2 Manufacturing

6.2.3 Distribution & Sales

6.2.4 Post-Sales Monitoring

7 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

7.1 Introduction

7.2 Treatment

7.3 Diagnosis

8 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

8.1 Introduction

8.2 Intravenous

8.3 Oral

9 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

9.1 Introduction

9.2 Hospitals

9.3 Specialty Neurological Clinics

9.4 Research & Academic Laboratories

10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 China

10.4.2 Japan

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East and Africa

10.5.1 Middle East

10.5.2 Africa

11 Competitive Landscape

11.1 Company Market Share Analysis

11.2 Introduction

12 Company Profiles

12.1 Grifols

12.1.1 Company Overview

12.1.2 Financial Overview

12.1.3 Products/Services Offered

12.1.4 SWOT Analysis

12.1.5 Key Developments

12.1.6 Key strategy

12.2 Shire

12.2.1 Company Overview

12.2.2 Financial Overview

12.2.3 Products/Services Offered

12.2.4 SWOT Analysis

12.2.5 Key Developments

12.2.6 Key strategy

12.3 Baxter

12.3.1 Company Overview

12.3.2 Company Overview

12.3.3 Products/Services Offered

12.3.4 SWOT Analysis

12.3.5 Key Developments

12.3.6 Key strategy

12.4 Pfizer, Inc.

12.4.1 Company Overview

12.4.2 Financial Overview

12.4.3 Products/Services Offered

12.4.4 SWOT Analysis

12.4.5 Key Developments

12.4.6 Key Strategy

12.5 CSL Behring

12.5.1 Company Overview

12.5.2 Financial Overview

12.5.3 Products/Services Offered

12.5.4 SWOT Analysis

12.5.5 Key Developments

12.5.6 Key Strategy

12.6 Kedrion S.p.A

12.6.1 Company Overview

12.6.2 Financial Overview

12.6.3 Products/Services Offered

12.6.4 SWOT Analysis

12.6.5 Key Development

12.6.6 Key Strategy

12.7 Octapharma

12.7.1 Company Overview

12.7.2 Financial Overview

12.7.3 Products/Services Offered

12.7.4 SWOT Analysis

12.7.5 Key Development

12.7.6 Key Strategy

12.8 Momenta Pharmaceuticals

12.8.1 Company Overview

12.8.2 Financial Overview

12.8.3 Products/Services Offered

12.8.4 SWOT Analysis

12.8.5 Key Development

12.8.6 Key Strategy

12.9 Teijin Pharma Limited

12.9.1 Company Overview

12.9.2 Financial Overview

12.9.3 Products/Services Offered

12.9.4 SWOT Analysis

12.9.5 Key Developments

12.9.6 Key strategy

12.1 Mitsubishi Tanabe Pharma Corporation

12.10.1 Company Overview

12.10.2 Financial Overview

12.10.3 Products/Services Offered

12.10.4 SWOT Analysis

12.10.5 Key Developments

12.11 Bio Products Laboratory Ltd.

12.11.1 Company Overview

12.11.2 Financial Overview

12.11.3 Products/Services Offered

12.11.4 SWOT Analysis

12.11.5 Key Developments

12.11.6 Key strategy

13 Appendix

13.1 Discussion Blue Print


List Of Figure

List of Figures:

 

FIGURE 1 RESEARCH PROCESS

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

(CIDP) MARKET

FIGURE 4 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET

FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET

FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS,

2017 (%)

FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2017 & 2023 (USD MILLION)

FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF

ADMINISTRATION, 2017 (%)

FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2017 & 2023 (USD MILLION)

FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2017 (%)

FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2017 & 2023 (USD MILLION)

FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2017 & 2023 (USD MILLION)

FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%)

FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%)

FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%)

FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE,

BY COUNTRY, 2017 (%)

FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2017 (%)


List Of Table

List of Tables:

 

TABLE 1 MARKET SYNOPSIS

TABLE 2 PRIMARY INTERVIEWS

TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION,

2015-2023 (USD MILLION)

TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION,

2015-2023 (USD MILLION)

TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRAVENOUS BY REGION,

2015-2023 (USD MILLION)

TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION,

2015-2023 (USD MILLION)

TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2015-2023 (USD MILLION)

TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION,

2015-2023 (USD MILLION)

TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS,

BY REGION, 2015-2023 (USD MILLION)

TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC

LABORATORIES, BY REGION, 2015-2023 (USD MILLION)

TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 26 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 27 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 28 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 29 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 30 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 31 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 32 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 33 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 34 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 35 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 36 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 37 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 38 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 39 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 40 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 41 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 42 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 43 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 44 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 45 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 46 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 47 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 48 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 49 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 50 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 51 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 52 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 53 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

\2015-2023 (USD MILLION)

TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 75 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 76 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 77 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 78 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 79 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 80 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 82 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 83 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 84 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 85 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 86 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 87 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 88 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 89 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 90 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 91 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 92 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 93 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 94 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

TREATMENT BY TYPE, 2015-2023 (USD MILLION)

TABLE 95 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION)

TABLE 96 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 97 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 98 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 99 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 100 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 101 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 102 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 103 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 104 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 105 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2015-2023 (USD MILLION)

TABLE 106 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 107 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 108 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 109 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 110 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 111 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 112 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 113 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 114 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 115 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 116 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 117 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 118 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 119 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 120 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 121 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 122 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 123 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 124 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 125 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 126 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 127 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 128 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 129 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

TABLE 130 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 131 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 132 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 133 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 134 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 135 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 136 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 137 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 138 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 139 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 140 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 141 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 142 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 143 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 144 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 145 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 146 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 147 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 148 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION,

2015-2023 (USD MILLION)

TABLE 149 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2015-2023 (USD MILLION)

TABLE 150 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2015-2023 (USD MILLION)

TABLE 151 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2015-2023 (USD MILLION)

TABLE 152 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 153 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION)

TABLE 154 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 155 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 156 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 157 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 158 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2015-2023 (USD MILLION)

TABLE 159 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 160 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2015-2023 (USD MILLION)

TABLE 161 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2015-2023 (USD MILLION)

TABLE 162 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2015-2023 (USD MILLION)

TABLE 163 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2015-2023 (USD MILLION)

TABLE 164 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2015-2023 (USD MILLION)

TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2015-2023 (USD MILLION)

TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION)

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter